Identification of Biomarkers for Cervical Cancer Radiotherapy Sensitivity and Survival Prognosis
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.This study identified six key radiotherapy sensitivity genes (RSGs) in cervical cancer, with IL1RAP and GPR15 linked to poorer survival. These RSGs may predict treatment response and offer new therapeutic targets for improving radiotherapy efficacy.
Area Of Science
- Oncology
- Molecular Biology
- Genomics
Background
- Radiotherapy resistance is a major cause of treatment failure in cervical cancer.
- Understanding the molecular basis of radiotherapy response is crucial for improving patient outcomes.
Purpose Of The Study
- To identify radiotherapy sensitivity genes (RSGs) in cervical cancer.
- To explore the association of RSGs with patient prognosis, immune infiltration, and drug sensitivity.
Main Methods
- Meta-analysis of gene expression datasets (GSE3578, GSE6213) to identify differentially expressed genes (DEGs).
- Utilized TCGA-CESE data to pinpoint RSGs and analyze their correlation with survival, immune cells, and drug sensitivities.
- Validated candidate RSG expression in an independent patient cohort using quantitative polymerase chain reaction (qPCR).
Main Results
- Identified 518 DEGs, with 305 upregulated and 213 downregulated during radiotherapy.
- Discovered six key RSGs significantly associated with radiotherapy response.
- IL1RAP and GPR15 upregulation correlated with poor survival prognosis; IL1RAP expression was higher in complete responders.
- RSG expression linked to M2 macrophage and γδT cell infiltration and altered drug sensitivities.
Conclusions
- Identified RSGs show potential as predictive biomarkers for radiotherapy response in cervical cancer.
- These RSGs may serve as novel therapeutic targets to enhance radiotherapy efficacy.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
